Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Federico Alberici"'
Autor:
Alessandra Pola, Nicole Zambetti, Margherita Venturini, Stefano Possenti, Francesca Valerio, Nicola Bossini, Francesco Scolari, Chiara Manenti, Stefania Affatato, Camilla Maffei, Federico Alberici, Mario Gaggiotti, Marianna Moscato, Laura Econimo, Elisa Delbarba
Publikováno v:
Kidney International
The outcome of SARS-CoV2 infection in patients who have received a kidney allograft and are being treated with immunosuppression is unclear. We describe 20 kidney transplant recipients (median age 59 years [inter quartile range 51-64 years], median a
Autor:
Francesco Tamborini, Federico Alberici, Piergiorgio Messa, Augusto Vaglio, Mariele Gatto, Francesca Radice, Giulia Frontini, Lucia Sacchi, Gabriella Moroni, Andrea Doria, Barbara Trezzi, Valentina Binda, Silvana Quaglini, Renato Alberto Sinico, Francesca Saccon
ObjectivesShort-term predictive endpoints of chronic kidney disease (CKD) are needed in lupus nephritis (LN). We tested response to therapy at 1 year.MethodsWe considered patients with LN who underwent renal biopsy followed by induction therapy betwe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b945cac428c772570c825dbe4441203d
http://hdl.handle.net/11379/532055
http://hdl.handle.net/11379/532055
Autor:
Julia Kerschbaum, Andreas Kronbichler, Rachel B Jones, David Jayne, Federico Alberici, Rona M Smith, Seerapani Gopaluni, Joanna Tieu
Publikováno v:
Annals of the Rheumatic Diseases
ObjectiveWe aimed to assess risk factors for the development of severe infection in patients with antineutrophil cytoplasm antibody-associated vasculitis (AAV) receiving rituximab.Methods192 patients with AAV were identified. Univariate and multivari
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc67705d38a8fb5ce562d00f87668b04
Autor:
Maurizio Gallieni, Piergiorgio Messa, Giacomo Emmi, Rachel B Jones, Giovanni Casazza, Frances Hall, Augusto Vaglio, Gabriella Moroni, Maria Letizia Urban, David Jayne, Rona M Smith, Federico Alberici, Renato Alberto Sinico, Matthias A. Cassia
Publikováno v:
Arthritisrheumatology (Hoboken, N.J.)References. 71(10)
Objective The efficacy of rituximab (RTX) in systemic lupus erythematosus (SLE) is a subject of debate. This study was undertaken to investigate the outcomes of RTX treatment in a European SLE cohort, with an emphasis on the role of RTX as a maintena
Autor:
Domenico Corradi, Jean-François Emile, Stefania Ferretti, Massimo De Filippo, Raphaël Saffroy, Guido Jeannin, Gabriella Becchi, Davide Gianfreda, Rosario Foti, Augusto Vaglio, Carlo Buzio, Federico Alberici, Marcella Di Gangi, Gabriella Moroni, Giorgio Baldari, Maricla Galetti, Maria Nicastro
Publikováno v:
Blood. 126:1163-1171
Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis, to whose pathogenesis neoplastic and immune-mediated mechanisms contribute. Mammalian target of rapamycin (mTOR)-inhibitors have antiproliferative and immunosuppressive proper
Autor:
Elena Oliva, Rosaria Santi, Lucio Manenti, Augusto Vaglio, Simeone Andrulli, Bruno Tumiati, Maria Letizia Urban, Alberto Pesci, Chiara Grasselli, Federica Maritati, Francesca Santarsia, Laura Pavone, Carlo Buzio, Alessandra Palmisano, Federico Alberici
Publikováno v:
PLoS ONE, Vol 12, Iss 10, p e0185880 (2017)
PLoS ONE
PLoS ONE
Objectives The treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is based on remission-induction and remission-maintenance. Methotrexate is a widely used immunosuppressant but only a few studies explored its role fo
Autor:
Sebastiano Buti, Domenico Potenzoni, Augusto Vaglio, Umberto Maggiore, Federico Alberici, Carlo Buzio, Rodolfo Passalacqua
Publikováno v:
Oncology. 76:69-76
Objective: We report the results obtained using an original immunotherapy schedule featuring chronically administered low-dose interleukin-2 (IL-2) and interferon-α (IFN-α) in patients with metastatic renal cell carcinoma (mRCC), and we assess trea
Autor:
Darren M. Roberts, Rachel B Jones, David Jayne, Dinakantha S. Kumaratne, Federico Alberici, Stella Burns, Rona M Smith
The anti-CD20 B cell depleting monoclonal antibody rituximab is being used increasingly for autoimmune diseases, including patients with refractory disease with extensive prior exposure to immunosuppressive treatments. Rituximab, in this context, may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::493be127041342bcd8ed159056e11ebb
http://hdl.handle.net/11379/527202
http://hdl.handle.net/11379/527202
Autor:
Rachel B Jones, Afzal N. Chaudhry, Rona M Smith, David Jayne, Kenneth G. C. Smith, Lisa C. Willcocks, Federico Alberici, Darren M. Roberts
Objective. ANCA-associated vasculitis (AAV) is characterized by a chronic relapsing course. Rituximab (RTX) is an effective maintenance treatment; however, the long-term outcomes after its discontinuation are unclear. The aim of this study was to exp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1aa378593e70e33c86f57f1128459040
http://hdl.handle.net/11379/527179
http://hdl.handle.net/11379/527179
Autor:
Darren M. Roberts, Dinakantha S. Kumaratne, David Jayne, Stella Burns, Rachel B Jones, Federico Alberici, Rona M Smith
Publikováno v:
Journal of autoimmunity. 57
Rituximab is a B cell depleting monoclonal antibody used to treat lymphoma and autoimmune disease. Hypogammaglobulinemia has occurred after rituximab for lymphoma and rheumatoid arthritis but data are scarce for other autoimmune indications. This stu